Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) reported disappointing results from two Phase 3 clinical trials investigating FMX101 to treat moderate to severe acne sending the stock price plummeting $3.80 to close at $5.30.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|